The New Frontier for Improved Access to Medicines

What’s at Stake?

Biologics, many of which are specialty medicines, are the most rapidly growing segment of increasing brand-name prescription drug costs in the U.S., with more than $100 billion in annual spending. Between April 2013 and March 2014, five of the 12 biggest selling drugs in the United States were biologics. Over the next few years, the number of biosimilar medicines available to patients will grow dramatically. In fact, by 2020, brand biologic medicines worth an estimated $81 billion in global annual sales will lose their patents, opening those markets for lower cost biosimilar alternatives.

Recent data show that the cost of many biologics is increasing at a faster annual pace than any other component in health care. It is expected that the biologics market will increase at a rate of more than 20 percent per year, and that by 2025, more than 70 percent of new drug approvals will be biological products. In 2014, United States spending for biologic medicines was approximately $115 billion, but it is expected to exceed $250 billion by 2019. This means that nearly $5 out of every $10 the country spends on prescription drugs will be spent on biologics.

In addition to the opportunity to provide millions of patients with lower-cost alternatives to brand biologic therapies, there are billions of dollars of savings at stake for America’s taxpayers. Estimates from various economic impact studies pin the projected savings from $44 billion on the low end to as high as $250 billion over 10 years and $378 billion over 20 years. While statistical assumptions for each analysis vary, experts agree on the transformative potential and significant savings from biosimilars.

Smart Trade Policies

To achieve the goal of ensuring access to biosimilars throughout the world, it is critical that trade agreements do not erect barriers that would grant lengthy monopoly protections to brand-name biologics manufacturers. U.S. biosimilars companies rely heavily on the ability to market their products abroad. Imposing additional exclusivity in trade agreements would prevent or delay such sales, to the detriment of this growing industry and patient access.

In addition to expanding patient access and reducing health care costs, increasing the affordability of biologic medicines may help to lower the deficit and improve the fiscal soundness of the United States government.

As governments cope with aging populations and an increase in chronic disease, the demand for affordable biologic alternatives will continue to grow. The introduction of safe and effective biosimilar therapies into the markets around the world has been proven to reduce health care costs while at the same time delivering lifesaving treatments to patients in need.

Patients with these conditions: Are waiting for the first or additional biosimilar products to these biological products in order to increase access:
Rheumatoid Arthritis Adalimumab (Humira®)
Etanercept (Enbrel®)
Rituximab (Rituxan®)
Infliximab (Remicade®)
Juvenile Idiopathic Arthritis Adalimumab (Humira®)
Etanercept (Enbrel®)
Psoriatic Arthritis Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)
Ankylosing Spondylitis Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)
Crohn’s Disease, Ulcerative Colitis Adalimumab (Humira®)
Infliximab (Remicade®)
Plaque Psoriasis Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)
Non-Hodgkin’s Lymphoma Rituximab (Rituxan®)
Chronic Lymphocytic Leukemia Rituximab (Rituxan®)
Metastatic Colorectal Cancer Bevacizumab (Avastin®)
Non-squamous Non-Small Cell Lung Cancer Bevacizumab (Avastin®)
Metastatic Renal Cell Carcinoma Bevacizumab (Avastin®)
Multiple Sclerosis Interferon Beta-1A (Rebif®)
HER2 Overexpressing Breast Cancer Trastuzumab (Herceptin®)
HER2 Overexpressing Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Trastuzumab (Herceptin®)
Non-Myleloid Malignancies receiving myelosuppressive anti-cancer drugs Pegfilgrastim (Neulasta®)
Neovascular (wet) Age-Related Macular Degeneration; Macular Edema Following Retinal Vein Occlusion (RVO); Diabetic Macular Edema Ranibizumab (Lucentis®)